Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Skin Laboratory PCLBKK:SKIN +3.53%20 EBITDA Margin % is -19.40% as of Mar. 2026. GuruFocus rates BKK:SKIN with a GF Score™ of 20/100. The stock has 2 warning signs investors should review. Among 1,957 Consumer Packaged Goods companies, Skin Laboratory PCL ranks worse than 90.29% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Skin Laboratory PCL's EBITDA for the
three
months ended in Mar. 2026 was ฿-7.0 Mil. Skin Laboratory PCL's Revenue for the
three
months ended in Mar. 2026 was ฿35.9 Mil. Therefore, Skin Laboratory PCL's EBITDA margin for the quarter that ended in Mar. 2026 was -19.40%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Skin Laboratory PCL EBITDA Margin % Related Terms
Skin Laboratory PCL EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Skin Laboratory PCL's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BKK:SKIN vs PG, CL, KVUE: EBITDA Margin % Comparison
For the Household & Personal Products subindustry, Skin Laboratory PCL's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Skin Laboratory PCL EBITDA Margin % vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Skin Laboratory PCL's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Skin Laboratory PCL's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Skin Laboratory PCL (BKK:SKIN) has a EBITDA Margin % of -19.40% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Skin Laboratory PCL and its competitors. According to the industry distribution chart, Skin Laboratory PCL ranks #1767 out of 1957 companies in the Consumer Packaged Goods industry, placing it in the top 90.3%.
Is Skin Laboratory PCL's EBITDA Margin % too high?
Skin Laboratory PCL's current EBITDA Margin % is -19.40%. Based on the distribution chart, Skin Laboratory PCL ranks #1767 out of 1957 companies in the Consumer Packaged Goods industry, which is in the bottom quartile relative to peers. Overall, Skin Laboratory PCL has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Skin Laboratory PCL's EBITDA Margin % compare to PG and CL?
According to the Consumer Packaged Goods industry distribution chart, Skin Laboratory PCL ranks #1767 out of 1957 companies for EBITDA Margin %. This places Skin Laboratory PCL in the lower half of its industry. The industry median EBITDA Margin % is 8.97. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Consumer Packaged Goods company?
The median EBITDA Margin % among Consumer Packaged Goods companies is 8.97, based on 1,957 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Skin Laboratory PCL and its competitors. For the Consumer Packaged Goods industry, the median EBITDA Margin % is 8.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Skin Laboratory PCL's current EBITDA Margin % is -19.40%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Skin Laboratory PCL stock overvalued right now?
Skin Laboratory PCL (BKK:SKIN) has a current EBITDA Margin % of -19.40%. The current EBITDA Margin % is -19.40%. Skin Laboratory PCL's overall GF Score™ is 20/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Skin Laboratory PCL (BKK:SKIN), the current EBITDA Margin % is -19.40% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Skin Laboratory PCL is engaged in the business of inventing, developing, contracting production, and distributing beauty products under the Company's various brands, including facial serum products, sunscreen products, facial cleansers, facial care products, and other products. The Company's core business is only one operating segment, which is manufacturing and distributing skin creams, beauty creams, cosmetics, and operates virtually its business in one geographical location in Thailand.
20GF Score
Get the complete analysis for BKK:SKIN
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BKK:SKIN has been successfully added to your 
